validated questionnaires

Florian Lordick, Prof. Dr.

Bend Alt-Epping, PD Dr.

Anja Mehnert, Prof. Dr.

Birgitt van Oorschot, Prof. Dr.

Michael Thomas, Prof. Dr.

The aim of this non-investigational study is to determine the symptoms and disease burden at the time point of diagnosis and in the further course of an incurable cancer disease. The needs and preferences of patients suffering from cancer (ovarian carcinoma, breast cancer, malignant melanoma, lung cancer, stomach cancer, oesophageal cancer, pancreatic cancer, cancer of the hepatobiliary system, colorectal cancer, head and neck cancer) are examined by various validated questionnaires. The data obtained by these questionnaires are collected together with information obtained by the treating physicians at four time points during the study: t0 - patient´s enrollment, at the moment of diagnosis and before the start of tumor therapy, respectively; T1 - 3 months after patient´s enrollment; T2 - 6 months after patient´s enrollment; T3 - 12 months after patient´s enrollment. This highly innovative project offers the chance to identify medical services deficits and risk circumstances for the burden of treatments in an oncology-palliative setting and to optimize the quality of patient care.

Assessment of Disease Burden and Palliative Care Needs of Patients During the Course of Incurable Cancer Disease

Florian Lordick, MD

Prof. Dr. med. (MD, PhD)

Blood and Lymph Conditions

All Conditions

Heart and Blood Diseases

Rare Diseases

Myeloproliferative Disorders

Primary Myelofibrosis

Thrombocytosis

Thrombocythemia, Essential

Bone Marrow Diseases

Hematologic Diseases

Blood Platelet Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Hemorrhagic Disorders

Chronic Myeloproliferative Disorders

Essential Thrombocythemia

Patients will be categorized as low-risk using Dynamic International Prognostic Scoring System (DIPSS) risk OR intermediate-1 risk by DIPSS by reason of age alone.

Patients will be age ≥ 60 years OR have history of thromboembolic events OR currently receiving ET-directed therapy.

Robyn M. Scherber, MD, MPH

The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy

Incyte Corporation

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Assessment of Disease Burden and Palliative Care Needs of Patients During the Course of Incurable Cancer Disease	NCT02751723	Cancer Disease,...	validated quest...	18 Years -	University of Leipzig
Assessment of Disease Burden and Palliative Care Needs of Patients During the Course of Incurable Cancer Disease	NCT02751723	Cancer Disease,...	validated quest...	18 Years -	University of Leipzig
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)	NCT02953704	MPN (Myeloproli...		18 Years -	Incyte Corporation
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)	NCT02953704	MPN (Myeloproli...		18 Years -	Incyte Corporation

Spots Global Cancer Trial Database for disease burden